Integrins are widely expressed receptors that primarily function as mediators of cell-extracellular matrix interactions. They have multiple physiological roles, and alterations in their structure and function result in pathological conditions in multicellular organisms. Selective targeting of integrins is a therapeutic modality that can impact disease processes which are major causes of morbidity and mortality. This is most clearly seen in vascular disease, where anti-integrin agents are routinely used for treating acute ischaemic myocardial conditions. In the future, therapeutic targeting of integrins may also play a role in the treatment of inflammatory and neoplastic conditions. In this review we discuss the mechanisms whereby integrins are involved in thrombotic vascular conditions, inflammation and neoplasia, and outline how they can be targeted as therapeutic modalities.
Read full abstract